UK markets closed

argenx SE (ARGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
293.500.00 (0.00%)
At close: 12:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close293.50
BidN/A x N/A
AskN/A x N/A
Day's range293.50 - 293.50
52-week range130.00 - 305.50
Avg. volume8
Market cap20.446B
Beta (5Y monthly)1.03
PE ratio (TTM)N/A
EPS (TTM)-11.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

    Translational data from Phase 2 study of efgartigimod in pemphigus further demonstrate argenx’s scientific leadership in FcRn biology, providing new insights into pathophysiology of autoimmune skin blistering diseases and potential role of FcRn blockadeData to be included in symposium presentation at Society for Investigative Dermatology (SID) Annual Meeting being held today, May 19, 2022, 7:30am PT May 19, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology co

  • Globe Newswire

    argenx announces results of Annual General Meeting of Shareholders

    May 10, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that all proposed resolutions at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed. As part of the approved resolutions: The company's annual report and annual accounts for the financial year ending December 31, 2021, were approved;The advisory vote on

  • Globe Newswire

    argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

    Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless of prior therapy or disease severity Statistically significant separation from placebo in key platelet-derived secondary endpoints Safety and tolerability profile of VYVGART is consistent with previous clinical trials; ADVANCE is first registrational trial with chronic dosing out to 24 weeks Topline